• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Etanercept in the treatment of rheumatoid arthritis
【24h】

Etanercept in the treatment of rheumatoid arthritis

机译：依那西普治疗类风湿关节炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Biologic agents have transformed clinical outcomes in rheumatoid arthritis, and there are now several immune-modulating therapies available. Tumour necrosis factor-α (TNF-α) inhibitors were the first biologic drug class licensed for the treatment of rheumatoid arthritis. Etanercept is a fusion protein composed of two TNF receptors bound to the constant portion (Fc) of human immunoglobulin G (IgG). Areas covered: This article will consider the pharmacological properties of etanercept and the clinical efficacy data presented in clinical trials. Its safety in clinical practice will be reviewed. Expert opinion: There is overwhelming evidence to support the use of etanercept in rheumatoid arthritis. Trial data demonstrate etanercept's efficacy in reducing structural damage, improving clinical outcomes and inducing remission. Optimal response to therapy is seen when used in combination with methotrexate and when initiated early. Etanercept is an attractive therapeutic option given the excellent safety profile, reduced immunogenicity and ease of administration.
机译：简介：生物制剂已经改变了类风湿关节炎的临床疗效，现在有几种免疫调节疗法可供使用。肿瘤坏死因子-α（TNF-α）抑制剂是第一种获准用于治疗类风湿关节炎的生物药物。 Etanercept是一种融合蛋白，由两个与人免疫球蛋白G（IgG）恒定部分（Fc）结合的TNF受体组成。涵盖领域：本文将考虑依那西普的药理特性和临床试验中提供的临床疗效数据。将对它在临床实践中的安全性进行审查。专家意见：有大量证据支持依那西普用于类风湿关节炎。试验数据表明依那西普在减少结构损伤，改善临床结果和诱导缓解方面的功效。当与甲氨蝶呤联用时以及提早开始治疗时，可以看到对治疗的最佳反应。鉴于出色的安全性，降低的免疫原性和易于给药，依那西普是一种有吸引力的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号